Novavax (NVAX) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nvx-Cov2705 | Covid-19, Sars-Cov-2 Infection | Phase IV | Not Yet Recruiting | Efficacy and Safety of NVX-CoV2705 | Jul 17, 2025 | ― |
| Nvx-Cov2705 | Covid-19, Sars-Cov-2 Infection | Phase III | Not Yet Recruiting | Safety and Immunogenicity of NVX-CoV2705 | Jul 14, 2025 | ― |
| Protein Subunit: Novavax Covid-19 Vaccine, Pfizer Mrna Covid-19 Vaccine | Covid-19, Sars Cov 2 Infection, Vaccine-Preventable Diseases | Phase IV | Active Not Recruiting | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | Oct 04, 2024 | ― |
| Coformulated Cic Vaccine, Fluzone Hd Trivalent | Influenza, Covid-19 | phase2AndPhase3 | Withdrawn | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | Jun 27, 2024 | ― |
| Tniv 1 And Matrix-M Adjuvant | Covid-19 | phase2AndPhase3 | Withdrawn | Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | Jun 27, 2024 | ― |
| Nvx-Cov2705 Vaccine | Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Phase III | Completed | A Strain Change Study for SARS-CoV-2 rS Vaccines | May 08, 2024 | ― |
| Cic Vaccine Co-Formulated Tniv2 , Sarscov-2 Rs And Matrix-M Adjuvant, Novavax Covid-19 Vaccine, Tniv Vaccine, Fluzone High Dose | Covid-19 | Phase III | Active Not Recruiting | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | Mar 01, 2024 | ― |
| Nvx-Cov2601 Co-Formulated Omicron Xbb.1.5 Sars-Cov-2 Rs Vaccine, Prototype/Xbb.1.5 Bivalent Vaccine (5 Μg) | Covid-19 | Phase III | Completed | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | Jul 31, 2023 | ― |
| Xbb.1.5 Vaccine (Booster), Xbb.1.5 Vaccine (Single Dose) | Covid-19 | phase2AndPhase3 | Completed | A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. | Jul 28, 2023 | ― |
| Nvx-Cov2373 (5Μg), Nvx-Cov2601 (5Μg), Nvx-Cov2601(5Μg), Nvx-Cov2601 (35Μg), Nvx-Cov2601(35Μg), Nvx-Cov2601(50Μg), Bivalent Ba.4/5 | Covid-19 | phase2AndPhase3 | Completed | Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | Jun 27, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Nvx-Cov2705 | Phase IV | Covid-19, Sars-Cov-2 Infection | Not Yet Recruiting | Efficacy and Safety of NVX-CoV2705 | Jul 17, 2025 | ― |
| Nvx-Cov2705 | Phase III | Covid-19, Sars-Cov-2 Infection | Not Yet Recruiting | Safety and Immunogenicity of NVX-CoV2705 | Jul 14, 2025 | ― |
| Protein Subunit: Novavax Covid-19 Vaccine, Pfizer Mrna Covid-19 Vaccine | Phase IV | Covid-19, Sars Cov 2 Infection, Vaccine-Preventable Diseases | Active Not Recruiting | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States | Oct 04, 2024 | ― |
| Coformulated Cic Vaccine, Fluzone Hd Trivalent | phase2AndPhase3 | Influenza, Covid-19 | Withdrawn | Lot Consistency Study of COVID-19 and Influenza Combination Vaccine | Jun 27, 2024 | ― |
| Tniv 1 And Matrix-M Adjuvant | phase2AndPhase3 | Covid-19 | Withdrawn | Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine | Jun 27, 2024 | ― |
| Nvx-Cov2705 Vaccine | Phase III | Severe Acute Respiratory Syndrome Coronavirus 2 Infection | Completed | A Strain Change Study for SARS-CoV-2 rS Vaccines | May 08, 2024 | ― |
| Cic Vaccine Co-Formulated Tniv2 , Sarscov-2 Rs And Matrix-M Adjuvant, Novavax Covid-19 Vaccine, Tniv Vaccine, Fluzone High Dose | Phase III | Covid-19 | Active Not Recruiting | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine | Mar 01, 2024 | ― |
| Nvx-Cov2601 Co-Formulated Omicron Xbb.1.5 Sars-Cov-2 Rs Vaccine, Prototype/Xbb.1.5 Bivalent Vaccine (5 Μg) | Phase III | Covid-19 | Completed | Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines | Jul 31, 2023 | ― |
| Xbb.1.5 Vaccine (Booster), Xbb.1.5 Vaccine (Single Dose) | phase2AndPhase3 | Covid-19 | Completed | A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. | Jul 28, 2023 | ― |
| Nvx-Cov2373 (5Μg), Nvx-Cov2601 (5Μg), Nvx-Cov2601(5Μg), Nvx-Cov2601 (35Μg), Nvx-Cov2601(35Μg), Nvx-Cov2601(50Μg), Bivalent Ba.4/5 | phase2AndPhase3 | Covid-19 | Completed | Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines | Jun 27, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Novavax (CH:NVAX) have in its pipeline
Novavax CH:NVAX is currently developing the following drugs: Nvx-Cov2705, Protein Subunit: Novavax Covid-19 Vaccine, Pfizer Mrna Covid-19 Vaccine, Coformulated Cic Vaccine, Fluzone Hd Trivalent, Tniv 1 And Matrix-M Adjuvant, Nvx-Cov2705 Vaccine, Cic Vaccine Co-Formulated Tniv2 , Sarscov-2 Rs And Matrix-M Adjuvant, Novavax Covid-19 Vaccine, Tniv Vaccine, Fluzone High Dose, Nvx-Cov2601 Co-Formulated Omicron Xbb.1.5 Sars-Cov-2 Rs Vaccine, Prototype/Xbb.1.5 Bivalent Vaccine (5 Μg), Xbb.1.5 Vaccine (Booster), Xbb.1.5 Vaccine (Single Dose), Nvx-Cov2373 (5Μg), Nvx-Cov2601 (5Μg), Nvx-Cov2601(5Μg), Nvx-Cov2601 (35Μg), Nvx-Cov2601(35Μg), Nvx-Cov2601(50Μg), Bivalent Ba.4/5, Nvx-Cov2373, Sars-Cov-2 Rs Antigen/Matrix-M Adjuvant, Influenza Vaccine, Qniv Vaccine With Matrix-M Adjuvant, Cic Vaccine With Matrix-M Adjuvant, Sars-Cov-2 Rs Vaccine With Matrix-M Adjuvant, Sars-Cov-2 Rs/Matrix-M1 Adjuvant (Initial Vaccination Period), Nvx-Cov2373, Nvx-Cov2373, Nvx-Cov2515, Nvx-Cov2373 + Nvx-Cov2515, Nvx-Cov2540, Nvx-Cov2373 + Nvx-Cov2540, Nvx-Cov2373, Bbibp-Corv Vaccine, Sii B.1.351, Sii Bivalent, Sii B.1.617.2, Icc Vaccine, Qniv Nanoparticle Vaccine2 In-Clinic Mixed With Matrix-M1 Adjuvant, Sars-Cov-2 Rs Nanoparticle Vaccine In-Clinic Mixed With Matrix-M1 Adjuvant, Sars-Cov-2 Rs/Matrix-M1 Adjuvant (Initial Vaccination Period), Sars-Cov-2 Rs/Matrix-M1 Adjuvant (Crossover Vaccination Period), Sars-Cov-2 Rs/Matrix-M1 Adjuvant (Booster Vaccination), Sars-Cov-2 Rs/Matrix-M1 Adjuvant (Second Booster Vaccination), Sars-Cov-2 Rs/Matrix M1-Adjuvant, Licensed Seasonal Influenza Vaccine, Sars-Cov-2 Rs/Matrix-M1 Adjuvant, Sars-Cov-2 Rs - Phase 1, Sars-Cov-2 Rs/Matrix-M Adjuvant - Phase 1, Sars-Cov-2 Rs/Matrix-M Adjuvant, Day 0 - Phase 1, Sars-Cov-2 Rs/Matrix-M Adjuvant - Phase 2, Nanoflu, Fluzone Quadrivalent, Influenza Vaccine, Matrix-M Adjuvant, Nanoflu (Quad-Niv), Fluzone Hd, Flublok Quadrivalent, Nanoflu, Fluzone Hd - Day 0, Fluzone Hd - Day 21, Saline - Day 21, Rsv F Vaccine With Aluminum Phosphate Adjuvant, Rsv F Vaccine, Matrix-M1 Adjuvant, Phosphate Buffer, Rsv F Vaccine With Adjuvant, Formulation Buffer, Rsv-F Vaccine, Base Dose Ebov Gp Vaccine, 2X Base Dose Ebov Gp Vaccine, 4X Base Dose Ebov Gp Vaccine, 8X Base Dose Ebov Gp Vaccine, Matrix-M Adjuvant, Quadrivalent Vlp Vaccine, Comparator Tiv, Rsv F Vaccine With Adjuvant (0.5Ml Injection), Rsv F Vaccine (0.5Ml Injection), Hepatitis A Vaccine (0.5Ml Injection), Rsv F Vaccine (0.5Ml Injection), Monovalent Avian Influenza Vlp (H7n9), Matrix-M1™ Adjuvant, Low Dose Rsv F Antigen, High Dose Rsv F Antigen, Dose 1 Of Aluminum Adjuvant, Dose 2 Of Aluminum Adjuvant, Dose 3 Of Aluminum Adjuvant, Dose 4 Of Aluminum Adjuvant. These drug candidates are in various stages of clinical development as the company works toward FDA approval.